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Key points 
Question What is the effect of multinutrient supplementation and food-related behavioral activation 
therapy on prevention of a new episode of major depressive disorder among overweight or obese adults 
with depressive symptoms? 
Findings: In this 2x2 factorial randomized clinical trial that included 1025 adults, there was no significant 
difference in episodes of major depressive disorder over 1 year follow-up with multinutrient 
supplementation vs placebo (54 (10.5%) vs 51 (9.9%)) or with food-related behavioral activation therapy 
vs no therapy (48 (9.4%) vs 57 (11.1%)).   
Meaning: These findings do not support the use of multinutrient supplementation or food-related 
behavioral activation therapy for prevention of major depressive disorder. 
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Abstract 
Importance: Effects of nutritional interventions on the prevention of major depressive disorder (MDD) in 
overweight adults are unknown. 
Objective: To examine the effect of two nutritional strategies (multi-nutrient supplementation, food-
related behavioral activation (F-BA) therapy) and their combination for prevention of a new MDD 
episode in overweight adults with subsyndromal depressive symptoms.    
Design, setting, participants: This multicenter 2x2 factorial randomized clinical trial included overweight 
adults (BMI 25-40kg/m2) aged 18-75years with elevated depressive symptoms (Patient Health 
Questionnaire-9 (PHQ-9) scores≥5) not meeting criteria for MDD episodes in the past 6 months from 4 
European countries. 1025 adults were randomized between July-30-2015 and October-12-2016, and 
followed for 1 year (until October-13-2017).  
Interventions: Daily multi-nutrient supplements (1412mg omega-3 fatty acids, 30μg selenium, 400μg 
folic acid, and 20μg D-3 vitamin plus 100mg calcium) versus placebo (blinded), and/or 21 individual and 
group F-BA sessions versus no F-BA (blinded to researchers), for one year. Participants were allocated to 
placebo without F-BA (n=257), placebo with F-BA (n=256), supplements without F-BA (n=256), and 
supplements with F-BA (n=256). 
Main Outcomes and Measures: Primary outcome was cumulative 1-year onset of MDD measured with 
the Mini International Neuropsychiatric Interview after 3, 6 and 12 months. Logistic regression using 
effect-coded variables (-1 indicating control, +1 indicating intervention) evaluated intervention effects 
both individually and in combination (interaction) on MDD onset. 
Results: Among 1025 participants (mean age 46.5y; 772 (75%) women; mean BMI 31.4kg/m2), 779 (76%) 
completed the trial.  
During 12 month follow-up, 105 (10%) developed MDD (placebo without F-BA: 25 (9.7%), placebo with F-
BA: 26 (10.2%), supplements without F-BA: 32 (12.5%), supplements with F-BA: 22 (8.6%)..  Neither 
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supplements (odds ratio (OR)=1.06; 95%-confidence interval (CI)=0.87-1.29), F-BA (OR=0.93; 95%CI=0.76-
1.13), nor their combination (OR=0.93; 95%CI=0.76-1.14, p for interaction=0.48) affected MDD onset. 
Number of deaths/hospitalizations were for placebo without F-BA (n=0,n=24), placebo with F-BA 
(n=0,n=24), supplements without F-BA (n=0,n=26) and supplements with F-BA (n=1,n=24), respectively.   
Conclusions and Relevance: Among overweight or obese adults with depressive symptoms, multi-
nutrient supplementation compared with placebo and food-related behavioral activation therapy 
compared with no therapy did not reduce episodes of major depressive disorder during 1 year. These 
findings do not support the use of these interventions for prevention of major depressive disorder. 
Trial registration:  https://www.clinicaltrials.gov/ct2/show/NCT02529423. August-2015.  
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Introduction 
Major depressive disorder (MDD) is a common psychiatric disorder (lifetime prevalence 17%),1 ranking as 
the second leading contributor of years lived with disability.2  Prevention may offer an important 
opportunity to reduce the global disease burden of MDD.3  
One preventive strategy for MDD might be to modify diet. Prospective studies have found that 
better adherence to higher quality diets is associated with reduced future onset of depressive 
symptoms.4 Food-related behaviors, like unhealthy eating styles,5 have been cross-sectionally related to 
increased depressive symptoms. Recent randomized clinical trials (RCTs) found that dietary improvement 
strategies reduced depressive symptoms in depressed adults relative to control conditions,6,7 but there 
remains a clear lack of RCTs testing dietary strategies to prevent depression.8  
Similarly, observational studies have suggested that lower levels of specific nutrients (e.g. 
omega-3 polyunsaturated fatty acids, folic acid, vitamin D, selenium) are related to higher levels of 
depressive symptoms. 9,10 Some - but not all - nutritional supplement intervention studies have indicated 
that nutrient supplementation may reduce depressive symptoms in those with MDD.11 
 To date, few experimental studies have directly evaluated the effect of changing diet, food-
related behavior or nutrients on preventing MDD8,12  and none to our knowledge have specifically 
targeted overweight and obese individuals, who are a particularly relevant population,  given their 
increased risk for MDD and the key role of diet in these conditions.13 Therefore, the MooDFOOD 
depression prevention trial examined the effect of two different nutritional strategies (multi-nutrient 
supplementation, food-related behavioral activation therapy) and their combination for prevention of a 
new MDD episode in overweight people with subsyndromal depressive symptoms. 
 
Methods 
Study design 
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This study was a 2x2 factorial RCT  performed between July 30 2015 and October 13 2017 in four 
European countries (Germany, Spain, United Kingdom and The Netherlands). For full details of trial 
design and protocol see Roca et al.14 and Supplement 1. Ethics approval was provided by the Human 
Research Ethics Boards of the four study sites. All participants provided written informed consent. This 
manuscript reports on primary and secondary mental health outcomes as assessed up to 12 months.  
 
Recruitment and eligibility criteria 
Participants were recruited to participate in a study investigating new strategies to improve mood and 
wellbeing through changes in diet and lifestyle by the study sites (located in Leipzig; Palma de Mallorca; 
Exeter, UK; Amsterdam). Main eligibility criteria were age 18-75 years, body mass index (BMI) between 
25-40 kg/m2, having at least mild depressive symptoms as operationalized by Patient Health 
Questionnaire (PHQ-9) scores of ≥5,15 but having no current MDD episode (in past 6 months; Mini 
International Neuropsychiatric Interview 5.0 (MINI 5.0)16 (see Appendix 1 in Supplement 2 for 
recruitment details and eligibility). All eligible participants were invited to visit one of the study sites for a 
baseline interview, physical measurements, and blood sampling conducted by trained research 
assistants/nurses, and the completion of self-report questionnaires. Follow-up assessments took place at 
3, 6 and 12 months.  
 
Randomization 
At the end of the baseline interview, participants were randomized with equal probability to: (1) placebo 
supplements without F-BA; (2) placebo supplements with F-BA; (3) multi-nutrient supplements without 
F-BA; or (4) multi-nutrient supplements with F-BA by a permuted block randomization (block sizes 
ranging from 8-12; https://www.sealedenvelope.com). Randomization was stratified by study site and 
participants’ lifetime history of depression status. After randomization, researchers dispensed 
supplements to participants according to unique randomization codes. Participants, therapists, and 
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researchers were blind to supplement allocation. Participants of the F-BA intervention were contacted 
directly by the therapist, ensuring that researchers assessing follow-up outcomes remained blind to F-BA 
intervention status.  Statistical analyses on the primary outcome and the reported secondary outcomes 
in which participants were analyzed according to their randomization group were carried out blinded for 
randomization. 
 
Interventions 
Multi-nutrient supplements 
Patients received either multi-nutrient supplements (1412mg of eicosapentaenoic and docosahexaenoic 
omega-3 poly unsaturated fatty acids (PUFAs) (ratio 3:1), 30μg selenium , 400μg folic acid, and 20μg 
vitamin D3 coupled with 100mg calcium) or placebo, each provided in two pills per day, taken daily for 
one year (see Appendix 2 in Supplement 2 for details).  
 
Food-related behavioural activation therapy (F-BA) 
F-BA consisted of a protocol-based intervention that incorporated standard BA approaches. BA is 
effective in depression treatment,17 and includes self-monitoring, functional analysis, and activity 
scheduling. F-BA applied these proven techniques to improve mood by changing dietary habits, food-
related behaviours (e.g., snacking), increasing positive behaviours and emphasising a Mediterranean-
style diet, which has been related to reduced depression onset.4  F-BA was provided in up to 21 sessions 
(15 individual, 6 group) for one year (see Appendix 3 in Supplement 2 for F-BA details). No active (e.g. 
attention) control condition was provided in those receiving no F-BA. 
 
Outcomes 
Primary outcome 
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Primary outcome was the 12-month cumulative onset of an episode of MDD, defined according to 
standard psychiatric Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) 
criteria, and measured with the depression section of the MINI 5.016 at 3, 6, and 12 months.  
 
Secondary outcomes 
Secondary trial outcomes were depression severity (PHQ-9, range 0-27 with higher values indicating 
higher severity ,15 Inventory of Depressive Symptomatology; IDS30-SR, range 0-84 with higher values 
indicating higher severity),18 anxiety severity (Generalized Anxiety Disorder-7; GAD-7, range 0-21 with 
higher values indicating higher severity),19  health-related quality of life (utility, EuroQol instrument EQ-
5D-5L20 using the value sets for England21, range 0-1, with higher values indicating better health utility), 
eating behavior (three factor eating questionnaire; TEFQ-R18, all three factors ranging from 0-100 with 
higher values indicating poorer eating behaviour)22 food behavior, food intake (GA2LEN food frequency 
questionnaire23), physical activity and sedentary behavior (short questionnaire to assess health-
enhancing physical activity; SQUASH24), and body weight perception (Stunkard25). This article paper 
reports on the mental health secondary outcomes depression severity (PHQ-9,15 IDS30-SR),18 anxiety 
severity (GAD-7),19  and utility (EQ-5D-5L; Appendix 4 in Supplement 2).20,21 Time to onset of first MDD 
episode was included for post-hoc analyses.  
 
Other measures 
Good adherence to interventions (attending ≥8 of 21 sessions for F-BA, and taking ≥70% of the 
supplements during the 12 months for supplements) was defined a priori. A detailed description of these 
and other measures can be found in Appendix 5 and 6 in Supplement 2. 
 
Sample size 
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Sample size was based on the primary outcome and accounted for the 2x2 factorial design. At the time 
the trial was designed, effective preventive interventions in high-risk groups were found to reduce the 
onset of depression by 25–50 %.3  Assuming a 33% reduction of MDD onset between active (20% MDD 
onset) versus control conditions (30% MDD onset),26,27 392 participants (196 in each of the four possible 
intervention combinations) were needed to evaluate the main effect of each of the two nutritional 
interventions (versus respective control) assuming a 2-sided test at α=0.05 and a power of (1−β)=0.90. 
Assuming a follow-up attrition rate of 22%, 250 participants per intervention combination were needed. 
This corresponds to an absolute difference of 10%, which is consistent with the assumed clinically 
relevant difference in depression onset, estimated by consulting clinical experts and stakeholders (e.g. 
health insurance companies), reported in a previous depression prevention trial.28 
 
Statistical methods 
Participants were analyzed according to their randomization group, including all participants randomized 
regardless of intervention actually received or study withdrawal. The two nutritional interventions were 
effect coded (-1 indicating control and +1 indicating intervention) and jointly modelled to efficiently 
study main effects and interactions as recommended for factorial designs.29 All analyses were adjusted 
for study site and history of MDD. Missing data for the trial endpoints were accounted for using multiple 
imputation under the missing at random (MAR) assumption into 100 datasets. Results were pooled using 
Rubin’s rules.30  
Logistic regression analyses were conducted to estimate effects of the interventions on the primary 
outcome. Cox proportional hazard modelling was used to study intervention effects on time to first MDD 
onset (3, 6 or 12 months for either MDD onset or last available measurement) as post-hoc analysis. 
Scaled Schoenfeld residuals were used to test the proportionality of hazard assumption, which was met 
(p>0.05). For secondary outcomes, Generalized Estimating Equations (GEE) longitudinal analysis of 
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covariance (ANCOVA) with an exchangeable correlation structure was used,31 modelling outcomes at 3, 
6, and 12 months as dependent variables, and adjusting for their corresponding baseline values. Overall 
follow-up effects (including all follow-up assessments) and 12-month effects of the interventions for 
these secondary follow-up outcomes were tested.31 Because of the potential for type 1 error due to 
multiple comparisons, findings for analyses of secondary endpoints should be interpreted as exploratory. 
Effect modification of study site and history of MDD was investigated with their corresponding 
interaction terms with the interventions. Similarly, effect modification by baseline symptom severity was 
included as post-hoc analyses. 
As GEE are known to be robust for missing data, GEE longitudinal ANCOVA without multiple imputation 
was carried out as sensitivity analyses. Cohens’ D was calculated for each baseline-12-month follow-up 
difference in secondary outcome between the intervention groups,32 using multiple imputed data. 
Furthermore, Complier Average Causal Effect (CACE) analyses33-34 were carried out with the multiple 
imputed data using structural equation modelling within STATA, to provide an estimate of intervention 
effects taking into account good adherence with the interventions, whilst retaining the benefits of 
randomization for both primary and secondary 12-months follow-up outcomes (Appendix 7 in 
Supplement 2). Analyses were conducted with R (version 3.4.4), the packages geepack, and  mice, were 
used for the GEE analyses, and multiple imputation,  respectively. The 2-sided significance threshold was 
set at p=0.05. 
 
 
Results 
Description of participants 
Between July-30-2015 and October-12-2016, 5965 individuals visited the online screening questionnaire, 
2235 participants fulfilled the key inclusion criteria, 1773 participants completed the subsequent 
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telephone screening, and 1250 were deemed eligible for the trial. After subsequent exclusion of 
individuals not willing/able to participate, 1025 adults were randomly allocated to receive placebo 
without F-BA (n=257), placebo with F-BA (n=256) multi-nutrient supplements without F-BA (n=256) and 
multi-nutrient supplements with F-BA (n=256). Table 1 shows the baseline characteristics of the 
intervention groups, the flow chart is described in Figure 1. 
 
Follow-up attrition  
The number of participants not taking part in follow-up assessment at 3, 6, and 12 months, was 194 
(19%), 254 (25%), and 246 (24%), respectively. Figure 1 shows numbers and main reasons for lost-to-
follow-up (defined as having no 12-months follow-up measurement, n=246). In total, 239 (23%) 
participants dropped out before the 12-month follow-up or before the main endpoint (onset of MDD) 
occurred. Missing rates for the primary outcome did not differ between the four intervention groups at 3 
months (p=0.47), 6 months (p=0.62), and 12 months (p=0.91). Missing rates for the secondary outcomes 
of depressive symptoms, anxiety symptoms and health utility scores obtained through self-report 
questionnaires were slightly higher: number of individuals with missing data at 0, 3, 6, and 12 months 
ranged from 29-32, 206-210, 275-278, and 268 for these outcomes, respectively. These missing rates did 
not differ across intervention groups.  
 
Adherence to interventions 
Appendix 8 in Supplement 2 describes adherence for each intervention group. Of all 12-month follow-up 
participants, pill weight data indicated that 77% of participants had adherence of >70% to the 
supplements/placebo. Of those randomized to F-BA, 71% attended ≥8 of 21 sessions. A median of 14 out 
of 15 individual sessions were attended (interquartile range IQR 6-15), and a median of 0 out of 6 group 
sessions (IQR 0-4) were attended, indicating that adherence to individual sessions was highest.  
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Onset of MDD 
105 participants (10%) developed a MDD episode during the 12-months follow-up (Table 2). The number 
of individuals developing MDD was 25 (9.7%) in those receiving placebo without F-BA, 26 (10.2%) in 
those receiving placebo with F-BA, 32 (12.5%) in those receiving supplements without F-BA, and 22 
(8.6%) in those receiving supplements with F-BA. Considering the main effect of each intervention the 
numbers of participants who developed MDD were 51 (9.9%; 1.1 per 100 person-months) in those 
receiving placebo, 54 (10.5%; 1.2 per 100 person-months) in those receiving supplements, 57 (11.1%; 1.3 
per 100 person-months) in those not receiving F-BA and 48 (9.4%; 1.0 per 100 person-months) in those 
receiving F-BA.  Logistic regression using effect-coded intervention variables (-1,1) showed no significant 
effect of supplements (OR=1.06, 95%CI 0.87-1.29, p=0.57) or F-BA (OR=0.93, 95%CI 0.76-1.13, p=0.47) or 
significant supplements-by-F-BA interaction (OR=0.93, 95%CI 0.76-1.14, p for interaction=0.48) on the 
onset of MDD. There was no significant effect of supplements (HR=1.05, 95%CI 0.86-1.27, p=0.65) or F-
BA (HR=0.91, 95%CI 0.75-1.10, p=0.32) or significant supplements-by-F-BA interaction (HR=0.91, 95%CI 
0.75-1.11, p for interaction=0.36) on the time to first onset of MDD (Table 2).  
 
Depressive symptoms, anxiety symptom and health-related quality of life 
Figure 2 shows boxplots and means of the secondary outcome scores at baseline, 3, 6 and 12 months 
stratified by F-BA and supplement groups (see Appendix 9 in Supplement 2 for figure stratified by the 
four intervention combinations) . There were no significant supplement-by-F-BA interactions for any of 
the secondary outcome scores (p-values for interaction ranging from 0.41 to 0.98).  Table 3 presents 
effects on secondary outcomes. F-BA was significantly related to lower anxiety GAD scores at 12 months 
follow-up (adjusted mean difference=-0.48, 95%CI-0.84 to -0.12,p=0.01; unadjusted baseline GAD for no 
F-BA=5.8), unadjusted baseline GAD for F-BA=5.8, unadjusted 12-month follow-up GAD for no F-BA=3.9, 
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unadjusted 12 month follow-up GAD for F-BA=3.2), but not on other secondary outcomes. There was a 
significant effect of supplements on overall follow-up measures of the PHQ (adjusted mean 
difference=0.65, 95%CI 0.25-1.06,p=0.002), IDS (adjusted mean difference=1.20, 95%CI 0.29-
2.10,p=0.01) and GAD (adjusted mean difference=0.50, 95%CI 0.16-0.84,p=0.004) scores, and on PHQ 
scores at 12 months follow-up (adjusted mean difference=0.56, 95%CI 0.11-1.01,p=0.02; unadjusted 
baseline PHQ for placebo=7.3), unadjusted baseline PHQ for supplements=7.5, unadjusted 12-month 
follow-up PHQ for placebo=4.1, unadjusted 12-month follow-up PHQ for supplements=4.9), showing less 
improvement in depressive and anxiety symptoms relative to placebo. 
Effect modification and sensitivity CACE analyses 
Appendix 10 in Supplement 2 shows the results of post-hoc effect modification analyses by study site, 
history of depression and baseline symptoms scores. These analyses suggested that 1) the effect of F-BA 
on PHQ at 12 months follow-up was more favorable (larger reduction) when baseline PHQ depression 
severity was higher, 2) use of supplements resulted in higher follow-up anxiety scores when baseline 
anxiety severity scores were higher, and 3) that the effect of F-BA on health utility scores at 12-month 
follow-up was larger in the United Kingdom compared to the Netherlands. Sensitivity analyses for 
depression, anxiety, and health utility scores without multiple imputed data gave comparable effect 
estimates (Appendix 11 in Supplement 2). The results of the CACE analyses were consistent with the 
original analyses, finding no effect of supplements on the primary outcome, and similar effects for 
secondary outcomes (Appendix 12 in Supplement 2). CACE analyses found a significant effect of F-BA on 
the primary outcome (OR 0.78; 95% CI 0.64-0.95), accounting for treatment adherence. 
 
Adverse events and concealment 
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98 participants were hospitalized and 1 participant died during the 12-month follow-up, these events 
were judged as unrelated to interventions (Appendix 8 in Supplement 2). Those receiving placebo were 
less likely to believe they were taking multi-nutrients compared to those receiving multi-nutrients 
(placebo without F-BA 8.2%, placebo with F-BA 10.4%, multi-nutrients without F-BA: 25.5%, multi-
nutrients with F-BA 43.7%, p<0.001; Appendix 13 in Supplement 2). 40.4% reported that they did not 
know their allocation. 
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Discussion 
This multi-center trial conducted in 1025 overweight individuals with subsyndromal depressive 
symptoms showed no effect of multi-nutrient supplements, F-BA, or their combination on the 1-year 
cumulative onset of MDD.  
To our knowledge, this is the first randomized trial evaluating the effectiveness of two nutritional 
strategies and their combination for the prevention of depression in a high-risk group of overweight 
people. Despite our large sample size and selection of people with elevated depressive symptoms, the 
onset of MDD was lower than expected, which reduced the statistical power to detect a statistically 
significant effect. Comparisons of intervention effects with other trials are difficult due to 
methodological and sample differences: compared to previous trials testing preventative psychological 
strategies for depression that found significant effects,35 our sample had on average lower initial levels of 
depressive symptoms, and lower likelihood of having a history of MDD, making them less vulnerable for 
MDD onset.   
The adherence to both interventions was adequate, with about three quarters fulfilling 
predefined adherence criteria for the interventions. For F-BA, the individual sessions in the first six 
months were well attended, but the group sessions in the subsequent six months were not.   
This study showed that multi-nutrient supplements containing omega-3 PUFAs, vitamin D, folic 
acid and selenium neither reduced depressive symptoms, anxiety symptoms, nor improved health utility 
measures. In fact, they appear to result in slightly poorer depressive and anxiety symptoms scores 
compared to placebo.  Despite substantial evidence of observational studies linking lower nutrient levels 
to higher depressive symptoms, similar to our findings, a review of nine RCTs found no support that 
vitamin D could prevent depression in older adults.12 For omega-3 PUFAs, one RCT in mild to moderately 
depressed individuals – a population that is somewhat comparable to our sample - also showed no 
favorable effect of omega-3 PUFAs on depressive symptoms.36 No effect of folic acid combined with 
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vitamin B6 and B12 was found on the onset of depression in older men37 and older women.38 
Furthermore, Rayman et al.39 found no effect of selenium on mood in older adults. Overall, the studies 
available thus far, including our own trial, do not support the use of nutritional supplementation in the 
prevention of depression.12   
F-BA had a significant effect on reduction in anxiety symptoms at 12 months, but not on any of 
the other secondary mental health outcomes. When accounting for a priori defined intervention 
adherence (i.e. attending ≥8 of 21 sessions), F-BA was related to lower MDD onset, with an effect size 
comparable to that reported  in (meta-analytic) studies of psychological interventions for 
depression.35,28,40 In a post hoc analysis, a more beneficial effect of F-BA on depressive symptoms for 
those with higher baseline depression scores was observed. This suggests that with sufficient dose and a 
higher risk sample, F-BA might prevent depression, although this requires further study. It would be 
relevant to study which characteristics make participants more likely to adhere to the intervention, to 
identify persons who may benefit from this intervention. 
Strengths of this study are its randomized 2x2 factorial design, inclusion of participants from four 
countries with different background characteristics and dietary patterns, its large sample size compared 
to other prevention studies of depression,35 intervention and follow-up period of one year, efficient 
testing of multiple nutrients, blinded design, measurement of multiple outcome assessments, and active 
adherence monitoring.  
Limitations 
This study has several limitations. First, the onset of MDD was lower than expected, which 
resulted in lower power to detect significant effects, if present. However, as placebo outperformed 
supplements for some secondary outcomes, it is unlikely that inclusion of an adequately powered 
sample would favor supplements for the prevention of depression. Second, a considerable number of 
participants (about a quarter) was lost to follow-up. Although this number was balanced between 
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intervention groups, attrition bias cannot be ruled out. Third, those who received placebo were less 
likely to believe they were taking multi-nutrients, which suggests that the blinding of participants was 
not optimal. Fourth, participants were not selected based on deficiencies in the specific nutrients 
provided. It is conceivable that deficient individuals will be more likely to benefit from supplementation, 
but studies addressing this are scarce.12 Fifth, no active control group for the F-BA component was 
present. Sixth, the pre-defined follow-up time of this study was one year, which might have been too 
short to detect an effect.   
Conclusions 
Among overweight or obese adults with subsyndromal depressive symptoms, multinutrient 
supplementation compared with placebo and food-related behavioral activation therapy compared with 
no therapy did not reduce episodes of major depressive disorder during 1 year. These findings do not 
support the use of these interventions for prevention of major depressive disorder in this population. 
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Table 1. Baseline sample characteristics of the trial stratified by intervention group 
 Placebo 
without Food-
related 
behavioural 
activation 
Placebo with 
Food-related 
behavioural  
activation 
Supplements 
without Food-
related 
behavioural 
activation 
Supplements 
with Food-
related 
behavioural 
activation 
N 257 256 256 256 
Sex     
    Females, n (%) 180 (70.0) 193 (75.4) 193 (75.4) 206 (80.5) 
    Males, n (%) 77 (30.0) 63 (24.6) 63 (24.6) 50 (19.5) 
Age in years, mean (SD), median 
(IQR) 
45.7 (13.2), 
47 (36-55) 
46.1 (12.8), 
47 (37-55) 
47.2 (13.3) 
48 (38-58) 
47.1 (12.7) 
47 (38-56) 
Site, n (%)     
   Germany 70 (27.2) 67 (26.2) 69 (27.0) 71 (27.7) 
    United Kingdom 64 (24.9) 63 (24.6) 64 (25.0) 63 (24.6) 
    Spain 64 (24.9) 64 (25.0) 62 (24.2) 62 (24.2) 
    The Netherlands 59 (23.0) 62 (24.2) 61 (23.8) 60 (23.4) 
Education, n (%)a     
   Low  25 (9.7) 21 (8.2) 31 (12.1) 26 (10.2) 
   Middle  124 (48.2) 141 (55.1) 120 (46.9) 113 (44.1) 
   High 108 (42.0) 94 (36.7) 105 (41.0) 117 (45.7) 
History of major depressive 
disorder,  n (%)  
83 (32.3) 89 (34.8) 88 (34.4) 83 (32.4) 
   2 or more episodes, n (%) 59 (23.0%) 53 (20.7%) 62 (24.2%) 58 (22.7%) 
Current smoker, n (%) 53 (20.6) 50 (19.5) 35 (13.7) 47 (18.4) 
Alcohol use (drinks/week), 
median (IQR) 
1.0 (0.2-3.7) 1.0 (0.2-3.7) 1.0 (0.2-3.7) 1.0 (0.2-3.7) 
Total physical activity (in 
hours/day), median (IQR)b 
7.8 (6.1-9.5) 7.8 (5.6-10.0) 7.9 (5.9-10.2) 7.5 (5.3-9.7) 
BMI kg/m2, mean (SD) 31.4 (4.1) 31.2 (3.9) 31.3 (4.0) 31.7 (3.9) 
Depression severity (PHQ-9), 
mean (SD), median (IQR)c 
7.3 (4.1) 
7 (4-10) 
7.3 (4.4) 
6 (4-10) 
7.9 (4.4) 
7 (5-10) 
7.1 (4.0) 
6 (4-9) 
Depression severity (IDS), mean 
(SD), median (IQR)d 
21.3 (9.8) 
20 (14-27) 
21.6 (10.5) 
21 (13-29) 
22.8 (10.2) 
21 (15-30) 
21.4 (9.8) 
20 (14-28) 
Anxiety severity (GAD-7), mean 
(SD), median (IQR)e 
5.8 (4.4) 
5 (3-7) 
6.2 (4.5) 
5 (3-9) 
5.7 (3.8) 
5 (3-7) 
5.4 (3.8) 
5 (3-7) 
Health utilityf (EQ5D5L), mean 
(SD), median (IQR)f 
0.87 (0.11) 
0.88 (0.82-
0.94) 
0.86 (0.13)  
0.87 (0.81-
0.95) 
0.86 (0.12) 
0.87 (0.81-
0.94) 
0.86 (0.12) 
0.88 (0.81-
0.94) 
MooDFOOD diet score, mean 
(SD)g 
51.7 (7.6) 51.9 (6.9) 51.6 (6.8) 51.4 (6.9) 
Prior (multi)-nutrient supplement 
use, n (%) 
77 (30.0) 86 (33.6) 78 (30.5) 79 (30.9) 
Abbreviations: EQ5D5L: EuroQol 5 dimension 5 level, GAD-7: Generalized Anxiety Disorder-7, IDS: Inventory of 
Depressive Symptomatology, IQR: Interquartile range,  
PHQ-9: Patient Health Questionnaire-9 
a low = no education, primary education or lower secondary education; middle = upper secondary education, post-
secondary non-tertiary education, short-cycle tertiary education; high = Bachelor, Master, Doctoral or equivalent 
level. 
b Total activity represents the number of hours/day spent on commuting (walking and cycling), work-related, 
household, leisure time and sport activities.  
f  
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cPHQ-9 score ranges from 0 to 27, with higher values indicating higher depression severity. PHQ score >=5 indicates 
mild depression. PHQ score >=10 indicates moderate depression. 
dIDS score ranges from 0 to 84, with higher values indicating higher depression severity. IDS score >=14 indicates 
mild depression. IDS score >=26 indicates moderate depression. 
eGAD-7 score ranges from 0 to 21, with higher values indicating higher anxiety severity. GAD score >=5 indicates 
mild anxiety. GAD score >=10 indicates moderate anxiety. 
fEQ5D5L score ranges from 0 to 1, with higher values indicating higher health utility (0 equaling death, 1 equaling 
full health). Health utility is based on the tariff of England, which is an algorithm that can be used to attach values 
to all health states derived from the health-related quality-of-life EQ5D5L instruments, reflecting a country-specific 
preference on health states. 
gMooDFOOD diet score ranges from 0 to 77, with higher values indicating better adherence to the 
Mediterranean-style diet that was promoted in the F-BA group. The MooDFOOD diet score consisted of 
11 components, and the median self-reported intake of each component was: vegetables (2.8 
times/day), fruit (1.9 times/day), fish (1.5 times/week), legumes/pulses (1 times/week), meat (5 
times/week), whole grain products (67% of total grains), low-fat dairy (0.9 times/day), olive oil (33% of 
total dressings, cooking oils and fats), soft drinks (0.14 times/day), processed food (1.6 times/day), and 
alcohol (0.14 times/day). 
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Table 2. Effect of supplements and food-related behavioural activation (F-BA) therapy on MDD onset 
 
Primary outcome: 12 month MDD onset 
 N 
 
Number of 
events 
No. of follow-
up dropouts a 
Imputed OR 
(95% CI)b pb 
Placeboc  513 51  113 Ref  
Supplementsd 512 54  126 1.06 (0.87-1.29) 0.57 
No F-BAe 513 57 122 Ref  
F-BAf  512 48  117 0.93 (0.76-1.13) 0.47 
Supplements by F-BAg NA NA NA 0.93 (0.76-1.14) 0.48 
Post-hoc outcome: time to MDD onset 
 Time to 
event or 
censoring 
(person 
months) 
Number of 
events 
 No. of 
follow-up 
dropouts e HR (95% CI) p 
Placebo  4656 51  113 Ref  
Supplements 4488 54  126 1.05 (0.86-1.27) 0.65 
No F-BA  4503 57 122 Ref  
F-BA  4641 48  117 0.91 (0.75-1.10) 0.32 
Supplements by F-BAg NA NA NA 0.91 (0.75-1.11) 0.36 
Models were adjusted for interventions, site and history of MDD. F-BA and pills were effect-coded (-1,1). CI=confidence interval, HR=hazard ratio, MDD=major 
depressive disorder, NA=not applicable, OR=odds ratio. 
a n that did not complete 12 months follow-up and had no MDD at previous follow-up measurements 
b derived from multiply imputed data.  
c Events/Total (%): Placebo without F-BA 25/257 (9.7%); Placebo with F-BA 26/256 (10.2%) 
d  Events/Total (%): Supplements without F-BA 32/256 (12.5%); Supplements with F-BA 22/256 (8.6%) 
e Events/Total (%): Placebo without F-BA 25/257 (9.7%); Supplements without F-BA 32/256 (12.5%) 
f Events/Total (%): Placebo with F-BA 26/256 (10.2%); Supplements with F-BA 22/256 (8.6%) 
g interaction between F-BA and supplements 
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Table 3. Effect of supplements and food-related behavioural activation (F-BA) therapy on secondary outcomes 
Outco
mes 
 Overall follow-up effect using all 
follow-upsa 
Effect at 12 month 
follow-upb 
  
  Estimate (95% CI) P Estimate (95% CI) P Cohens’ D 
PHQ  Supplements vs Placebo (ref) 0.33 (0.12 to 0.53) 0.002 0.28 (0.05 to 0.50) 0.02 0.10 
 F-BA vs no F-BA (ref) -0.13 (-0.33 to 0.07) 0.19 -0.17 (-0.39 to 0.06) 0.14 -0.02 
IDS Supplements vs Placebo (ref) 0.60 (0.15 to 1.05) 0.01 0.36 (-0.19 to 0.90) 0.20 0.05 
 F-BA vs no F-BA (ref) -0.23 (-0.67 to 0.22) 0.32 -0.28 (-0.83 to 0.27) 0.31 0.006 
GAD Supplements vs Placebo (ref) 0.25 (0.08 to 0.42) 0.004 0.14 (-0.04 to 0.33) 0.13 0.10 
 F-BA vs no F-BA (ref) -0.16 (-0.32 to 0.01) 0.06 -0.24 (-0.42 to -0.06) 0.01 -0.07 
Utility Supplements vs Placebo (ref) -0.006 (-0.012 to 0.000) 0.052 -0.002 (-0.008 to 0.005) 0.61 -0.07 
 F-BA vs no F-BA (ref) 0.002 (-0.003 to 0.008) 0.44 0.004 (-0.002 to 0.009) 0.23 0.08 
The two interventions and their interactions were modelled together. All models were adjusted for study site, history of MDD, and for the baseline value of the 
corresponding outcome measure. F-BA and pills were effect-coded (-1,1), Supplement-by-F-BA interaction effects were not included in the model because none 
of the interactions were significant. 
estimate= unstandardized regression coefficient, CI=confidence interval, NA=not applicable, SE=standard error,   
, GAD=Generalized Anxiety Disorder-7, IDS=inventory of depressive symptomatology OR=odds ratio, PHQ-9=Patient Health Questionnaire-9. 
To obtain adjusted mean differences in outcomes between the intervention conditions, the estimates and 95% confidence interval should be multiplied by 2. 
Cohen’s D calculated from baseline and 12 month follow-up means and pooled standard deviations obtained from multiple imputed data.   
aEstimates were obtained from generalized estimating equations longitudinal GEE analyses using effect-coded interventions based on multiply imputed data.  
bEstimates  were obtained from robust linear regression analyses based on multiply imputed data.  
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Figure titles and legends 
 
Figure 1. Flow chart of the MooDFOOD depression prevention trial 
 
BMI=body mass index, PHQ=Patient Health Questionnaire 
 
 
Figure 2. Course of depressive symptoms, anxiety symptoms and health utility per intervention group 
 
 
The boxplot inner horizontal lines represent the median, the boxes represent the interquartile range (25% and 75%), the vertical whiskers 
represent the 1.5 interquartile range beyond the 25th and 75th percentiles, and the dots represent all other values. The diamonds represent the 
means, which were connected with orange/blue lines. 
N represents the number of persons that completed the secondary outcomes at the different time points. Data shown are the available data.  
 
